Management of hyponatremia and clinical use of vasopressin antagonists

American Journal of the Medical Sciences

Volumn 333, Issue 2, 2007, Pages 101-105

  Oh, Man S ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

AVP receptor antagonists; Hyponatremia; Management of hyponatremia

Indexed keywords

ARGIPRESSIN; ARGIPRESSIN RECEPTOR; CLARITHROMYCIN; CONIVAPTAN; CYTOCHROME P450 3A4; DEMECLOCYCLINE; DIGOXIN; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LITHIUM; LIXIVAPTAN; PLACEBO; RITONAVIR; SODIUM; SODIUM CHLORIDE; TOLVAPTAN; VASOPRESSIN ANTAGONIST;

AREA UNDER THE CURVE; CLINICAL PROTOCOL; CLINICAL TRIAL; DEHYDRATION; DISEASE CLASSIFICATION; DIZZINESS; DRUG CLEARANCE; DRUG ELIMINATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; HYPONATREMIA; HYPOTENSION; INJECTION SITE REACTION; KIDNEY FAILURE; MATHEMATICAL MODEL; NAUSEA; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SKIN SENSITIVITY; THIRST; TREATMENT INDICATION; UREMIA; WATER DEPRIVATION; WATER RETENTION; XEROSTOMIA;

EID: 33847081706     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200702000-00006     Document Type: Article

References (44)

1. Oh MS, Carroll HJ. Disorders of sodium metabolism: hypernatremia and hyponatremia. Crit Care Med 1992;20:94-103.
2. Kumar S, Berl T. Sodium. Lancet 1998;352:220-8.
3. Robertson GL. Syndrome of inappropriate antidiuresis. N Engl J Med 1989;321:538-9.
4. Gines P, Abraham WT, Schrier RW. Vasopressin in pathophysiological states. Semin Nephrol 1994;14:384-97.
5. Arroyo V, Claria J, Salo J, et al. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis 1994;14:44-58.
6. Bichet D, Szatalowicz V, Chaimovitz C, et al. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 1982;96:413-7.
7. Schrier RW, Abraham W. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-85.
8. Thibonnier M. Genetics of vasopressin receptors. Curr Hypertens Rep 2004;6:21-6.
9. Berl T. Treating hyponatremia: damned if we do and damned if we don't. Kidney Int 1990;37:1006-18.
10. Sterns RH. The management of symptomatic hyponatremia. Semin Nephrol 1990;10:503-14.
11. Arieff AI, Ayus JC. Therapy of symptomatic hyponatremia: neither haste nor waste. Crit Care Med 1991;19:748-51.
12. Dubois GD, Arieff AI. Symptomatic hyponatremia: the case for rapid correction. In: Narins R, editors. Controversies in nephrology and hypertension. New York, NY: Churchill Livingstone; 1984.
13. Sterns RH. Severe symptomatic hyponatremia: treatment and outcome. A study of 64 cases. Ann Intern Med 1987;107:656-64.
14. Laureno R, Karp BI. Myelinolysis after correction of hyponatremia. Ann Intern Med 1997;126:57-62.
15. Sterns RH. Severe hyponatremia: the case for conservative management. Crit Care Med 1992;20:534-9.
16. Oh MS, Kim HJ, Carroll HJ. Recommendations for treatment of symptomatic hyponatremia. Nephron 1995;70:143-50.
17. Tomlinson BE, Pierides AM, Bradley WG. Central pontine myelinolysis. Q J Med 1976;45:373-86.
18. Norenberg MD, Leslie KO, Robertson AS. Association between rise in serum sodium and central pontine myelinolysis. Ann Neurol 1982;11:128-35.
19. Decaux G, Genette F. Urea for long-term treatment of syndrome of inappropriate secretion of antidiuretic hormone. Br Med J 1981;283:1081-3.
20. Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 2001;110:582-4
21. Decaux G, Mols P, Cauchie P, et al. Treatment of hyponatremic cirrhosis with ascites resistant to diuretics by urea. Nephron 1986;44:337-43.
22. Decaux G, Musch W, Soupart A. Hyponatremia in the intensive care: from diagnosis to treatment. Acta Clin Belg 2000;55-2:68-78.
23. Forrest JN Jr, Cox M, Hong C, et al. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 1978;298:173-7.
24. De Troyer A, Demanet JC, et al. Correction of antidiuresis by demeclocycline. N Engl J Med 1975;293:915-8.
25. White MG, Fetner CD. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with lithium carbonate. N Engl J Med 1975;292:390-2.
26. Curtis NJ, van Heyningen C, Turner JJ. Irreversible nephrotoxicity from demeclocycline in the treatment of hyponatremia. Age Ageing 2002;31:151-2.
27. Markowitz GS, Ravpakrishnan J, Kambham N, et al. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 2000; 11:1439-48.
28. 2 receptor antagonists. J Mol Endocrinol 2002;29:1-9.
29. Thibonnier M, Coles P, Thibonnier A, et al. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol 2001;41:175-202.
30. Agre P, Nielsen S. The aquaporin family of water channels in kidney. Nephrologie 1996;17:409-15.
31. Knepper MA. Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am J Physiol 1997;272:F3-F12.
32. Burrell LM, Risvanis J, Johnston CI, et al. Vasopressin receptor antagonism: a therapeutic option in heart failure and hypertension. Exp Physiol 2000;85(suppl):259S-65S.
33. Gerbes AL, Gulberg V, Gines P, et al; VPA Study Group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124:933-9.
34. Wong F, Blei AT, Blendis LM, et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003;37:182-91.
35. Gheorghiade M, Niazi I, Ouyang J, et al; for the Tolvaptan Investigators. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107: 2690-6.
36. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA 2004;291: 1963-71.
37. Verbalis JG, Bisaha JG, Smith N. Novel vasopressin V1A and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia [abstract]. J Am Soc Nephrol 2004;15:356A. Abstract SAP254.
38. Gross P, Bisaha JG, Smith N. Conivaptan, a novel V1A and V2 antagonist, increased serum sodium and effective water clearance in patients with euvolemic or hypervolemic hyponatremia [abstract]. J Am Soc Nephrol 2004;15:55A. Abstract SA-P243.
39. 2 antagonist conivaptan in patients with euvolemic or hypervolemic hyponatremia [abstract]. J Am Soc Nephrol 2004;15:355A. Abstract SA-P251.
40. Giebisch G. Renal potassium transport: mechanisms and regulation. Am J Physiol 1998;274:F817-33.
41. Vaprisol (Package insert). Deerfield, IL: Astellas Pharma US; 2005.
42. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology. 1995;104:1-8
43. Stiell I, Hebert P, Wells G, et al. Vasopressin versus epinephrine for inhospital cardiac arrest: a randomised controlled trial. Lancet 2001;358:105-9.
44. Dunser MW, Mayr AJ, Ulmer H, et al. The effects of vasopressin on systemic hemodynamics in catecholamineresistant septic and post-cardiotomy shock: a retrospective analysis. Anesth Analg 2001;93:7-13.